HIDRACENSUS 7.3


This is an ongoing, expert-led, insight-based programme, sponsored by UCB, that aims to improve the standard of care for patients living with hidradenitis suppurativa (HS) across Europe, through education and best practice sharing.

Meet our steering committee

Speaker 1

Professor Christos C. Zouboulis

Professor of Dermatology, Venereology and Allergology at the Faculty of Health Sciences, Brandenburg Medical School Theodor Fontane and Director of the Departments of Dermatology, Venereology, Allergology and Immunology, Städtisches Klinikum Dessau, Germany.
Speaker 2

Dr Barry McGrath

Co-founder and Manager of HS Ireland.
Speaker 3

Professor Gregor Jemec

Professor of Dermatology at the Health Sciences Faculty, University of Copenhagen and Head of Research at the Department of Dermatology, Zealand University Hospital in Denmark.
Speaker 4

Professor Falk G. Bechara

Head of the Department of Dermatologic Surgery, and Senior Physician at the Ruhr-University Bochum, Germany.
Speaker 5

Dr Fiona Collier

Recently retired General Practitioner (GPwSI in Dermatology), Scotland.
Speaker 6

Dr Antonio Martorell

Associate Professor of Dermatology at the Catholic University of Valencia, Spain.
Speaker 7

Professor Farida Benhadou

Professor of Dermatology, Director of the Clinic of Inflammatory Chronic Skin Diseases and Research Unit at the Department of Dermatology at the Erasmus Hospital, Brussels, Belgium.
Speaker 8

Professor Thrasyvoulos Tzellos

Dermatologist at the Department of Dermatology, NordlandssykehusetBodø, Norway, and Associate Professor at the Institute of Clinical Medicine, University of Tromsø, Norway.
Speaker 9

Professor Francesca Prignano

Associate Professor of Dermatology, Director of SOS “Chronic Inflammatory Skin Disease and Biologics”, Coordinator of the Master in Trichology Sciences, Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.

Why 7.3?

It takes a staggering 7.3 years, on average, for patients to receive a correct diagnosis of HS.1,2


HIDRACENSUS 7.3 aims to eliminate these diagnostic delays by educating all stakeholders and sharing best practice, to give patients the best chance of positive outcomes. 



Seven-point-three

The most important number for HS

Seven-point-three is a number

But to patients, it’s a prison sentence

HIDRACENSUS 7.3

Improved HS care starts here

References

1. Barmatz et al. Dermatology. 2022;238:772–84. 
2. Nguyen et al. J Eur Acad Dermatol Venereol. 2021;35:50–61.

GB-DA-2400152   |   June 2024

Terms & Conditions
Cookie Policy
Cookie Preferences

How will HIDRACENSUS 7.3 elevate the standard of HS care?

To achieve this, HIDRACENSUS 7.3 aims to: 


  • Gather up-to-date, relevant insights from all stakeholders, to gain a holistic understanding of the current standard of HS care and unmet needs.

     

  • Generate disease education initiatives, to increase the knowledge and understanding of HS for all those involved in caring for patients, including patients themselves.

     

  • Compile and expand upon existing best practices for the management of HS, and broaden access and use.

     

References

1. Barmatz et al. Dermatology. 2022;238:772–84. 
2. Nguyen et al. J Eur Acad Dermatol Venereol. 2021;35:50–61.

GB-DA-2400152   |   June 2024

Terms & Conditions
Cookie Policy
Cookie Preferences